BACKGROUND
Patients with non-Hodgkin’s lymphoma can present with complex clinical scenarios and a variety of clinical features including indolent disease, standard disease, and disease with aggressive phenotypes. This interview series talks about exciting developments in therapeutic options for patients with NHL in the first-line and relapsed/refractory settings.
In this segment the followed questions were posed by Dr Bruce Cheson:
Questions
- But of course many patients still relapse or are refractory to treatment. Let’s focus a little more closely on rituximab resistance – patients who progress or fail to respond, or progress within 6 months of treatment with rituximab-containing regimens. Resistance often develops concurrently in patients treated with chemoimmunotherapy. How well do we currently understand mechanisms of resistance?
- Can we say how widespread rituximab resistance is?
- What about in the maintenance setting, in practice are we defining resistance in the same way?
- What options do we currently have to circumvent resistance?
Support for the development of this video series was provided by the publisher, EJCMO.TV a subsidiary of San Lucas Medical, and was funded by a grant from Mundipharma Ltd.
Mundipharma had no editorial input into this series.
